Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

Data may be delayed or incomplete. Use at your own risk.

0.5 mg epinephrine - Phase 2 | SPRY Pipeline | CatalystAlert

Back to SPRY

0.5 mg epinephrine

Phase 2

ARS Pharmaceuticals, Inc. (SPRY)

16%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Jun 2026~

SPRY$1.0BPhase 2

0.5 mg epinephrine Phase 2 Results Expected

0.5 mg epinephrine • Urticaria Chronic

Drug Information

Target Indication

Urticaria Chronic

Clinical Trial

NCT06927999

Last updated: 12/4/2025

Regulatory Approvals

EMAPending

Neffy

Emergency treatment of allergic reactions, including anaphylaxis.

View on EMA

EMA8/22/2024

Eurneffy

Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children with a body weight ≥30 kg.

View on EMA

Developer

SPRY

ARS Pharmaceuticals, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

ARS-1Phase 2

Asthma

PlaceboPhase 2

Urticaria

View full pipeline